Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting loss of heterozygosity for cancer-specific immunotherapy.

Proceedings of the National Academy of Sciences of the United States of America - 23 Mar 2021

Hwang Michael S, Mog Brian J, Douglass Jacqueline, Pearlman Alexander H, Hsiue Emily Han-Chung, Paul Suman, DiNapoli Sarah R, Konig Maximilian F, Pardoll Drew M, Gabelli Sandra B, Bettegowda Chetan, Papadopoulos Nickolas, Vogelstein Bert, Zhou Shibin, Kinzler Kenneth W

Abstract excerpt

Developing therapeutic agents with potent antitumor activity that spare normal tissues remains a significant challenge. Clonal loss of heterozygosity (LOH) is a widespread and irreversible genetic alteration that is exquisitely specific to cancer cells. We hypothesized that LOH events can be therapeutically targeted by "inverting" the loss of an allele in cancer cells into an activating signal. Here we describe a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, Neoplasm
Share to Cell- and Tissue-Based Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HLA Antigens

Share to Immunotherapy

Share to Immunotherapy, Adoptive

Share to Loss of Heterozygosity

Share to Molecular Targeted Therapy

Share to Single-Chain Antibodies

Source

Open in PubMed Open full text

Identifiers

PMID: 33731480
DOI: 10.1073/pnas.2022410118
PMCID: PMC8000272

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting loss of heterozygosity for cancer-specific immunotherapy.PMID 33731480Read ↗

The Tmod cellular logic gate as a solution for tumor-selective immunotherapySemantic proximity Read ↗

Allele-specific HLA LOH in solid tumors: distinct patterns by tumor type and potential prognostic relevance.Semantic proximity Read ↗

Engineered T cells directed at tumors with defined allelic loss.Semantic proximity Read ↗

Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution.Semantic proximity Read ↗

Targeting cancer-specific mutations by T cell receptor gene therapy.Semantic proximity Read ↗

Validated machine learning algorithm with sub-clonal sensitivity reveals widespread pan-cancer human leukocyte antigen loss of heterozygositySemantic proximity Read ↗

Adoptive cell therapy targeting common p53 neoantigens in human solid cancersSemantic proximity Read ↗

A machine learning algorithm with subclonal sensitivity reveals widespread pan-cancer human leukocyte antigen loss of heterozygositySemantic proximity Read ↗

Loss of heterozygosity of essential genes represents a widespread class of potential cancer vulnerabilities.Semantic proximity Read ↗

Loss of heterozygosity of essential genes represents a widespread class of potential cancer vulnerabilitiesSemantic proximity Read ↗

Genetic engineering strategies to enhance antitumor reactivity and reduce alloreactivity for allogeneic cell-based cancer therapySemantic proximity Read ↗

Naturally Occurring Genetic Alterations in Proximal TCR Signaling and Implications for Cancer Immunotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.